These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

903 related articles for article (PubMed ID: 37186323)

  • 1. Rhabdomyolysis and statins: A pharmacovigilance comparative study between statins.
    Montastruc JL
    Br J Clin Pharmacol; 2023 Aug; 89(8):2636-2638. PubMed ID: 37186323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statin-related neurocognitive disorder: a real-world pharmacovigilance study based on the FDA adverse event reporting system.
    Xiao M; Li L; Zhu W; Wu F; Wu B
    Expert Rev Clin Pharmacol; 2024 Mar; 17(3):255-261. PubMed ID: 38275183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rhabdomyolysis a result of azithromycin and statins: an unrecognized interaction.
    Strandell J; Bate A; Hägg S; Edwards IR
    Br J Clin Pharmacol; 2009 Sep; 68(3):427-34. PubMed ID: 19740401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cataracts and statins. A disproportionality analysis using data from VigiBase.
    Macías Saint-Gerons D; Bosco Cortez F; Jiménez López G; Castro JL; Tabarés-Seisdedos R
    Regul Toxicol Pharmacol; 2019 Dec; 109():104509. PubMed ID: 31669197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimating the extent of reporting to FDA: a case study of statin-associated rhabdomyolysis.
    McAdams M; Staffa J; Dal Pan G
    Pharmacoepidemiol Drug Saf; 2008 Mar; 17(3):229-39. PubMed ID: 18175291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rhabdomyolysis with Co-Administration of Statins and Antiplatelet Therapies-Analysis of the WHO Pharmacovigilance Database.
    Roule V; Alexandre J; Lemaitre A; Chrétien B; Sassier M; Fedrizzi S; Beygui F; Dolladille C
    Cardiovasc Drugs Ther; 2023 Apr; ():. PubMed ID: 37115431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A survey of the FDA's AERS database regarding muscle and tendon adverse events linked to the statin drug class.
    Hoffman KB; Kraus C; Dimbil M; Golomb BA
    PLoS One; 2012; 7(8):e42866. PubMed ID: 22936996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statins and immune-mediated necrotizing myopathy: Variability in the risk.
    Trenque T; Hadjoudj J; Trenque A; Tralongo F; Martin S; Azzouz B
    Therapie; 2024; 79(3):365-370. PubMed ID: 37625939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of lovastatin/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the United States Food and Drug Administration adverse event reporting system).
    Alsheikh-Ali AA; Karas RH
    Am J Cardiol; 2007 Feb; 99(3):379-81. PubMed ID: 17261402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors for rhabdomyolysis with simvastatin and atorvastatin.
    Ronaldson KJ; O'Shea JM; Boyd IW
    Drug Saf; 2006; 29(11):1061-7. PubMed ID: 17061911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction potential between clarithromycin and individual statins-A systematic review.
    Hougaard Christensen MM; Bruun Haastrup M; Øhlenschlaeger T; Esbech P; Arnspang Pedersen S; Bach Dunvald AC; Bjerregaard Stage T; Pilsgaard Henriksen D; Thestrup Pedersen AJ
    Basic Clin Pharmacol Toxicol; 2020 Apr; 126(4):307-317. PubMed ID: 31628882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association Between Statin Use and Daptomycin-related Musculoskeletal Adverse Events: A Mixed Approach Combining a Meta-analysis and a Disproportionality Analysis.
    Chuma M; Nakamoto A; Bando T; Niimura T; Kondo Y; Hamano H; Okada N; Asada M; Zamami Y; Takechi K; Goda M; Miyata K; Yagi K; Yoshioka T; Izawa-Ishizawa Y; Yanagawa H; Tasaki Y; Ishizawa K
    Clin Infect Dis; 2022 Oct; 75(8):1416-1422. PubMed ID: 35262686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concomitant use of statins and sodium-glucose co-transporter 2 inhibitors and the risk of myotoxicity reporting: A disproportionality analysis.
    Gravel CA; Krewski D; Mattison DR; Momoli F; Douros A
    Br J Clin Pharmacol; 2023 Aug; 89(8):2430-2445. PubMed ID: 36912450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Onset timing of statin-induced musculoskeletal adverse events and concomitant drug-associated shift in onset timing of MAEs.
    Akimoto H; Negishi A; Oshima S; Okita M; Numajiri S; Inoue N; Ohshima S; Kobayashi D
    Pharmacol Res Perspect; 2018 Dec; 6(6):e00439. PubMed ID: 30443347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statins and erectile dysfunction: results of a case/non-case study using the French Pharmacovigilance System Database.
    Do C; Huyghe E; Lapeyre-Mestre M; Montastruc JL; Bagheri H
    Drug Saf; 2009; 32(7):591-7. PubMed ID: 19530745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs.
    Graham DJ; Staffa JA; Shatin D; Andrade SE; Schech SD; La Grenade L; Gurwitz JH; Chan KA; Goodman MJ; Platt R
    JAMA; 2004 Dec; 292(21):2585-90. PubMed ID: 15572716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of Statin-Associated Myopathy Case Reports in Thailand Using the Health Product Vigilance Center Database.
    Boonmuang P; Nathisuwan S; Chaiyakunapruk N; Suwankesawong W; Pokhagul P; Teerawattanapong N; Supsongserm P
    Drug Saf; 2013 Sep; 36(9):779-87. PubMed ID: 23615756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Muscle Damage Due to Fusidic Acid-Statin Interaction: Review of 75 Cases From the French Pharmacovigilance Database and Literature Reports.
    Bataillard M; Beyens MN; Mounier G; Vergnon-Miszczycha D; Bagheri H; Cathebras P
    Am J Ther; 2019; 26(3):e375-e379. PubMed ID: 29189310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Statin Associated Muscular Adverse Effects.
    Kammoun R; Charfi O; Lakhoua G; Zaiem A; Daghfous R; Kastalli S; Aouinti I; Aidli SE
    Curr Drug Saf; 2024; 19(1):114-116. PubMed ID: 36847228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.